Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
Kronos Bio, Inc. (KRON)
Company Research
Source: GlobeNewswire
– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects – – Poster presentation taking place on Thursday, October 24, 2024 – SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and autoimmune diseases driven by deregulated transcription, today announced that it will present preclinical data from its p300 KAT inhibitor program for human papillomavirus (HPV)-driven tumors at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held from October 23 to 25, 2024 in Barcelona, Spain. Kronos Bio is exploring the utility of its p300 KAT inhibitor, KB-9558, for HPV-driven tumors. In the presentation, the authors will show that the oncogenic HPV-16 virus hijacks the host transcriptional cofactor p300 in order to dri
Show less
Read more
Impact Snapshot
Event Time:
KRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRON alerts
High impacting Kronos Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KRON
News
- Kronos Bio announces interim CEO and workforce cuts of 83% [Yahoo! Finance]Yahoo! Finance
- Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul [Yahoo! Finance]Yahoo! Finance
- Kronos Bio Announces CEO Transition and Reduction in ForceGlobeNewswire
- Kronos Bio Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 [Yahoo! Finance]Yahoo! Finance
KRON
Earnings
- 11/13/24 - Beat
KRON
Sec Filings
- 11/27/24 - Form 8-K
- 11/15/24 - Form EFFECT
- 11/14/24 - Form SC
- KRON's page on the SEC website